Core Laboratories Inc. CLB
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 5.44M | 5.96M | -789.00K | 4.95M | 14.24M |
| Total Depreciation and Amortization | 3.72M | 3.83M | 3.76M | 3.67M | 3.59M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.06M | 3.09M | 1.77M | 8.47M | -4.44M |
| Change in Net Operating Assets | -7.26M | -5.06M | -778.00K | -9.14M | -4.89M |
| Cash from Operations | 4.97M | 7.81M | 3.97M | 7.95M | 8.50M |
| Capital Expenditure | -3.71M | -5.77M | -4.89M | -3.65M | -3.03M |
| Sale of Property, Plant, and Equipment | 70.00K | 1.58M | 1.49M | 668.00K | 152.00K |
| Cash Acquisitions | -- | -- | -- | -620.00K | 0.00 |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 451.00K | 254.00K | 9.00K | -148.00K | 5.27M |
| Cash from Investing | -3.19M | -3.93M | -3.39M | -3.75M | 2.39M |
| Total Debt Issued | 14.00M | 15.00M | 66.00M | 12.00M | 11.00M |
| Total Debt Repaid | -15.63M | -15.63M | -62.00M | -16.00M | -20.00M |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -1.05M | -2.69M | -4.00M | -2.66M | -5.01M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -459.00K | -460.00K | -460.00K | -466.00K | -465.00K |
| Other Financing Activities | -1.00K | -186.00K | -- | 1.00K | -1.98M |
| Cash from Financing | -3.14M | -3.96M | -457.00K | -7.12M | -16.45M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.36M | -84.00K | 117.00K | -2.93M | -5.56M |